Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29189008 | 0.81 | TSHR (0.32) | TSHR | |
| SCHEMBL235850 | 0.79 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL29468607 | 0.79 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL6508099 | 0.77 | TSHR (0.45) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL8999536 | 0.77 | TSHR (0.45) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL1642155 | 0.77 | TSHR (0.45) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL29726981 | 0.77 | TSHR (0.45) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL358581 | 0.75 | TSHR (0.43) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL20774081 | 0.75 | TSHR (0.43) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL2890886 | 0.75 | TSHR (0.43) | TSHRACHEALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038612-B1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3486237-A1 | TRIAZINONE DERIVATIVE CONTAINING SULFONYL STRUCTURE AND PREPARATION METHOD THEREFOR, AND INSECTICIDAL AND BACTERICIDAL USES THEREOF | Nankai University (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-2766362-B1 | SOLID FORMS OF NEMATOCIDAL SULFONAMIDES | DU PONT (US) | 2018-04-11 | — | — | EP | disclosed |
| CN-105175413-A | Solid Forms Of Nematocidal Sulfonamides | DU PONT | 2015-12-23 | — | — | CN | disclosed |
| US-9040554-B2 | Solid forms of nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2792360-A1 | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV | IP Gesellschaft für Management mbH (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2766362-A1 | SOLID FORMS OF NEMATOCIDAL SULFONAMIDES | E. I. Du Pont de Nemours and Company (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140228393-A1 | SOLID FORMS OF NEMATOCIDAL SULFONAMIDES | CORTEVA AGRISCIENCE LLC | 2014-08-14 | — | — | US | disclosed |
| CN-103857677-A | Solid forms of nematicidal sulfonamides | DU PONT | 2014-06-11 | — | — | CN | disclosed |
| WO-2013055584-A1 | SOLID FORMS OF NEMATOCIDAL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| US-5744600-A | VIRICIDES, ANTITUMOR AGENTS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1998-04-28 | — | — | US | disclosed |
| US-4697033-A | INSECTICIDES | SANDOZ LTD. (CH) | 1987-09-29 | — | — | US | disclosed |
| US-4654360-A | 1,2,3-trisubstituted indoles for treatment of inflammation | SYNTEX (U.S.A.) INC. (US) | 1987-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228393-A1 | SOLID FORMS OF NEMATOCIDAL SULFONAMIDES | MSL1, MLN, ABCG2 | TSHR 4091/4885ACHE 150/4885ALDH1A1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.